Skip to main content
. 2022 Mar 4;21(3):427–439. doi: 10.1158/1535-7163.MCT-21-0561

Figure 4.

Figure 4. Evaluation of clinically validated biomarkers in syngeneic tumor models. RNA-sequencing analysis was performed on five independent tumors across 11 syngeneic tumor mouse models after anti-PD-1 treatment. Tumors were harvested 4 days following the second dose of muDX400 or muIgG1 control antibody (treatment administered on day 0 and day 4). Models were classified as resistant, partial, or high as previously defined. A, Boxplots of Cd274 (Pdl1), depicting the absolute gene expression (log2 FPKM) across individual mouse in each tumor model grouped by responsiveness to muDX400 and by treatment. Significance determined by t test (NS, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). B, TMB (all somatic nonsynonymous mutations) and predicted neoantigens (total and expressed at the transcriptional level) are shown across the 11 mouse tumor cell lines (grown in vitro). None of the comparisons reached statistical significance (by t test) but they did show a trend (NS, P > 0.05). C, Individual count data. FPKM, fragments per kilobase million; muIgG1, mouse immunoglobulin G1; NS, not sufficient; PD-1, programmed death 1; TMB, tumor mutational burden.

Evaluation of clinically validated biomarkers in syngeneic tumor models. RNA-sequencing analysis was performed on five independent tumors across 11 syngeneic tumor mouse models after anti-PD-1 treatment. Tumors were harvested 4 days following the second dose of muDX400 or muIgG1 control antibody (treatment administered on day 0 and day 4). Models were classified as resistant, partial, or high as previously defined. A, Boxplots of Cd274 (Pdl1), depicting the absolute gene expression (log2 FPKM) across individual mouse in each tumor model grouped by responsiveness to muDX400 and by treatment. Significance determined by t test (NS, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). B, TMB (all somatic nonsynonymous mutations) and predicted neoantigens (total and expressed at the transcriptional level) are shown across the 11 mouse tumor cell lines (grown in vitro). None of the comparisons reached statistical significance (by t test) but they did show a trend (NS, P > 0.05). C, Individual count data. FPKM, fragments per kilobase million; muIgG1, mouse immunoglobulin G1; NS, not sufficient; PD-1, programmed death 1; TMB, tumor mutational burden.